All In Biotech

Free tool

FAERS Monitor: Giapreza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209360 or its brand name (Giapreza, Angiotensin Ii Acetate). Reports on generic versions are filed under their own applications.

Reports

300

Serious

273

91% of reports

Hospitalization

116

Death reported

95

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective72
  • off label use31
  • death26
  • acute kidney injury25
  • toxicity to various agents19
  • distributive shock17
  • peripheral ischaemia17
  • hypotension16
  • overdose16
  • intestinal ischaemia15
  • cardiac arrest13
  • cardiogenic shock12
  • bradycardia11
  • intentional overdose11
  • deep vein thrombosis10

Reports by year received

View as table
YearReports
20041
20072
20081
20093
20103
20117
201213
20131
20144
20152
20163
20173
201812
201929
202018
202130
202238
202343
202419
202534
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,859 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
distributive shockSignal17530.2333.58,396
peripheral ischaemiaSignal17293.1184.54,642
intestinal ischaemiaSignal15191.5116.92,649
cardiogenic shockSignal1258.733.7624
bradycardiaSignal1114.58.1126
intentional overdoseSignal1112.06.7101
acute kidney injurySignal2511.57.9230
cardiac arrestSignal1311.06.5109
deep vein thrombosisSignal1010.85.980
toxicity to various agentsSignal197.95.1109
hypotensionSignal165.63.556
overdoseSignal165.23.251
drug ineffectiveSignal723.83.1158
off label useSignal312.51.827
deathSignal262.11.515

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.